Relation of Black Race Between High Density Lipoprotein Cholesterol Content, High Density Lipoprotein Particles and Coronary Events (from the Dallas Heart Study)

American Journal of Cardiology

Volumn 115, Issue 7, 2015, Pages 890-894

  Chandra, Alvin ^a   Neeland, Ian J ^a   Das, Sandeep R ^a   Khera, Amit ^a   Turer, Aslan T ^a   Ayers, Colby R ^a   McGuire, Darren K ^a   Rohatgi, Anand ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AFRICAN AMERICAN; AGED; ATHEROSCLEROSIS; BLOOD; CLINICAL TRIAL; CORONARY ARTERY DISEASE; EPIDEMIOLOGY; ETHNOLOGY; FEMALE; HEALTH SURVEY; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE; PROCEDURES; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGED; ATHEROSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREVALENCE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TEXAS;

EID: 85027952408     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.01.015     Document Type: Article

References (20)

1. Mackey, R.H., Greenland, P., Goff, D.C. Jr., Lloyd-Jones, D., Sibley, C.T., Mora, S., High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 60 (2012), 508–516.
2. Mora, S., Glynn, R.J., Ridker, P.M., High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation 128 (2013), 1189–1197.
3. Victor, R.G., Haley, R.W., Willett, D.L., Peshock, R.M., Vaeth, P.C., Leonard, D., Basit, M., Cooper, R.S., Iannacchione, V.G., Visscher, W.A., Staab, J.M., Hobbs, H.H., Dallas Heart Study Investigators. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol 93 (2004), 1473–1480.
4. Khera, A., Vega, G.L., Das, S.R., Ayers, C., McGuire, D.K., Grundy, S.M., de Lemos, J.A., Sex differences in the relationship between C-reactive protein and body fat. J Clin Endocrinol Metab 94 (2009), 3251–3258.
5. Wallace, T.M., Levy, J.C., Matthews, D.R., Use and abuse of HOMA modeling. Diabetes Care 27 (2004), 1487–1495.
6. Jain, T., Peshock, R., McGuire, D.K., Willett, D., Yu, Z., Vega, G.L., Guerra, R., Hobbs, H.H., Grundy, S.M., Dallas Heart Study Investigators. African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study. J Am Coll Cardiol 44 (2004), 1011–1017.
7. Maroules, C.D., Rosero, E., Ayers, C., Peshock, R.M., Khera, A., Abdominal aortic atherosclerosis at MR imaging is associated with cardiovascular events: the Dallas Heart Study. Radiology 269 (2013), 84–91.
8. Gordon, D.J., Probstfield, J.L., Garrison, R.J., Neaton, J.D., Castelli, W.P., Knoke, J.D., Jacobs, D.R. Jr., Bangdiwala, S., Tyroler, H.A., High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989), 8–15.
9. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., Bairey Merz, C.N., Blum, C.B., Eckel, R.H., Goldberg, A.C., Gordon, D., Levy, D., Lloyd-Jones, D.M., McBride, P., Schwartz, J.S., Shero, S.T., Smith, S.C. Jr., Watson, K., Wilson, P.W., Eddleman, K.M., Jarrett, N.M., LaBresh, K., Nevo, L., Wnek, J., Anderson, J.L., Halperin, J.L., Albert, N.M., Bozkurt, B., Brindis, R.G., Curtis, L.H., DeMets, D., Hochman, J.S., Kovacs, R.J., Ohman, E.M., Pressler, S.J., Sellke, F.W., Shen, W.K., Smith, S.C. Jr., Tomaselli, G.F., 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 (2014), S1–S45.
10. Barter, P.J., Caulfield, M., Eriksson, M., Grundy, S.M., Kastelein, J.J., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.C., Waters, D.D., Shear, C.L., Revkin, J.H., Buhr, K.A., Fisher, M.R., Tall, A.R., Brewer, B., Investigators, I., Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007), 2109–2122.
11. AIM-HIGH Investigators Boden, W.E., Probstfield, J.L., Anderson, T., Chaitman, B.R., Desvignes-Nickens, P., Koprowicz, K., McBride, R., Teo, K., Weintraub, W., Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365 (2011), 2255–2267.
12. Schwartz, G.G., Olsson, A.G., Abt, M., Ballantyne, C.M., Barter, P.J., Brumm, J., Chaitman, B.R., Holme, I.M., Kallend, D., Leiter, L.A., Leitersdorf, E., McMurray, J.J., Mundl, H., Nicholls, S.J., Shah, P.K., Tardif, J.C., Wright, R.S., dal, O.I., Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367 (2012), 2089–2099.
13. HPS2-THRIVE Collaborative Group Landray, M.J., Haynes, R., Hopewell, J.C., Parish, S., Aung, T., Tomson, J., Wallendszus, K., Craig, M., Jiang, L., Collins, R., Armitage, J., Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371 (2014), 203–212.
14. Otvos, J.D., Collins, D., Freedman, D.S., Shalaurova, I., Schaefer, E.J., McNamara, J.R., Bloomfield, H.E., Robins, S.J., Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113 (2006), 1556–1563.
15. Keech, A., Simes, R.J., Barter, P., Best, J., Scott, R., Taskinen, M.R., Forder, P., Pillai, A., Davis, T., Glasziou, P., Drury, P., Kesaniemi, Y.A., Sullivan, D., Hunt, D., Colman, P., d'Emden, M., Whiting, M., Ehnholm, C., Laakso, M., FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005), 1849–1861.
16. Le, N.A., Jin, R., Tomassini, J.E., Tershakovec, A.M., Neff, D.R., Wilson, P.W., Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients. J Am Heart Assoc, 2, 2013, e000037.
17. Franceschini, G., Favari, E., Calabresi, L., Simonelli, S., Bondioli, A., Adorni, M.P., Zimetti, F., Gomaraschi, M., Coutant, K., Rossomanno, S., Niesor, E.J., Bernini, F., Benghozi, R., Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients. J Clin Lipidol 7 (2013), 414–422.
18. Burns, S.F., Lee, S., Arslanian, S.A., In vivo insulin sensitivity and lipoprotein particle size and concentration in black and white children. Diabetes Care 32 (2009), 2087–2093.
19. Vora, A.N., Ouyang, P., Bittner, V., Tardif, J.C., Waters, D.D., Vaidya, D., Racial differences of lipoprotein subclass distributions in postmenopausal women. Ethn Dis 18 (2008), 176–180.
20. Joshi, P.H., Toth, P.P., Lirette, S.T., Griswold, M.E., Massaro, J.M., Martin, S.S., Blaha, M.J., Kulkarni, K.R., Khokhar, A.A., Correa, A., D'Agustino, R.B. Sr., Jones, S.R., on behalf of the Lipoprotein Investigators Collaborative Study Group. Association of high-density lipoprotein subclasses and incident coronary heart disease: the Jackson Heart and Framingham Offspring Cohort Studies. Eur J Prev Cardiol, 2014.